INTRODUCTION
The inflammatory bowel diseases (IBDs), Crohn's disease (CD) and ulcerative colitis (UC), are chronic relapsing conditions affecting up to 1 in 250 of the adult population with up to 25% of IBD patients being diagnosed during childhood or adolescence (1) . In younger patients, disease morbidity can be significant, with the risk of lifelong consequences related to growth, reproductive health, education, future employment, and psychological well-being. IBD is widely believed to originate from a dysregulated immune response to luminal bacteria (2) . Empirical and epidemiological data have suggested an acute infective trigger is often present to herald the onset of disease in a genetically susceptible host (3) . Of the other environmental factors thought to impact disease susceptibility, only smoking and appendicectomy have a substantive evidence base (4) .
Concordance data in twins (36% for CD and 16% for UC, 4% for both CD and UC for monozygotic and dizygotic twins, respectively) and multiplex IBD families (relative risk to firstdegree relative of proband ≤35 for CD and ≤15 for UC) have provided strong epidemiological evidence for a genetic contribution to IBD susceptibility (5) . These observations led to the application of nonparametric linkage analysis in 11 genome-wide searches for regions of the genome involved in IBD during the 1990s ( Fig. 1) (6) .
The region on chromosome 16 (IBD1) was first identified by Jean-Pierre Hugot, a French pediatric gastroenterologist, in 1996 (7) . Fine mapping of this locus led to the identification of the NOD2/CARD15 gene (nucleotide-binding oligomerization domain 2)/CARD15 (caspase activation recruitment domain 15), a landmark discovery in complex disease genetics and the start of a lustrum of exponentially increasing knowledge of mucosal homeostasis (8) .
As the gut is continuously exposed to a vast array of microorganisms and dietary epitopes, mucosal homeostasis critically depends on organ-specific, physiological low-grade inflammation to deal with this wide array of antigens and integrity of the epithelial barrier. Pathogen-associated molecular pattern (PAMP) recognition through receptors of the innate immune system such as NOD-like receptors and toll-like receptors (TLRs) are crucial to the former. Involved in the latter aspect are genes like MDR1, DLG5, OCTN1&2, and MyosinIXb.
Advances in molecular genetics and an exponential reduction of genotyping costs have facilitated the leap from hypothesis-driven candidate gene research to hypothesis-free genome-wide studies, initially using linkage analysis but more recently genome-wide association studies. It has become evident that no technique should be considered the "gold standard;" rather we should acknowledge the contribution and limitations of each of these. Indeed, candidate gene analysis has been applied to regions identified through linkage analysis. The limitations of linkage analysis, such as requiring access to a large set of affected siblings and the difficulties encountered in trying to identify genes of weak effect, have led the research community to embrace genomewide association studies. This hypothesis-free search strategy involves the analysis of several hundred thousand markers, distributed across the whole genome. In order to separate true findings from the "statistical noise," stringent criteria for multiple testing (so-called "Bonferroni-correction") and replication of the findings in independent cohorts are required.
In this review, we discuss the IBD susceptibility genes for which the evidence is felt to be strongest (NOD2/CARD15
[CD], HLA region [CD/UC], MDR-1 [UC], as well as the recently implicated IL23R and ATG16L1 genes, discovered by genome-wide association studies). In addition, we will summarize the controversies regarding other putative IBD genes such as OCTN1&2 (IBD5 locus), NOD1/CARD4, TLR4, DLG5, ICAM-1, and MyosinIXb.
IBD SUSCEPTIBILITY GENES BEFORE GENOME-WIDE ASSOCIATION STUDIES

NOD2/CARD15
The discovery of NOD2/CARD15 was not only one of the first success stories in complex polygenic disease genetics but has also been responsible for a renewed interest in the innate immune response in IBD (2) . NOD2/CARD15 is a member of a family of intracellular NOD-like receptors, pattern-recognition receptors (PRRs) which recognize microbial components, also called PAMPs. NOD2/CARD15 expression appears to be limited to Paneth cells, which are located at the base of the intestinal crypts (9) . The three main CD-associated NOD2/CARD15 variants are situated in or close to the leucine-rich repeat (LRR) domain of the molecule. These mutations are thought to interfere with the recognition of muramyl dipeptide (MDP), a degradation product of peptidoglycan derived from the cell wall of Gramnegative and Gram-positive bacteria (Fig. 2) (10) . The association of NOD2/CARD15 variants with greater susceptibility to CD was confirmed in two comprehensive meta-analyses (11, 12) . However, as homozygosity/compound heterozygosity for the disease-associated alleles is not underrepresented in white healthy controls, NOD2/CARD15 clearly must act along with other, as yet unknown, factors to determine CD susceptibility (13) .
The strongest association of NOD2/CARD15 variant carriage with disease phenotype has consistently been with ileal disease, and the reduced secretion of α-defensins by ileal Paneth cells in patients carrying NOD2/CARD15 variants is important in this respect (11, 14) .
NOD2/CARD15: From Gene to Function
van Heel et al. concluded, after detailed functional analyses in human peripheral mononuclear cells, that the main CD-associated polymorphisms of NOD2/CARD15 cause a "loss of function" due to an MDP sensing defect (10) . However, as NOD2/CARD15 signaling is only one branch of a complex tree of innate immunity signaling pathways, these initial observations must be interpreted with caution (2). Indeed, conflicting results have been reported on the interaction between TLR-2 and wildtype NOD2/CARD15 signaling by Watanabe et al. and Netea et al. (15, 16) . As the mucosal immune system keeps the systemic immune system largely ignorant of the (commensal) bacteria it interacts with, and local immune responses are orchestrated in a tissue-specific manner, observations in transfected cell lines or even human peripheral blood mononuclear cells may prove to be of limited relevance to further our understanding of intestinal NOD2/CARD15 function (17, 18) .
Does the HLA Region Influence Susceptibility to IBD?
Genome-wide analysis as well as candidate gene studies implicate the human leukocyte antigen (HLA) region in CD and UC, with the evidence strongest in UC (19, 20) . The region on chromosome 6p (IBD3) containing the HLA genes as well as a myriad of functional IBD candidate genes like tumor necrosis factor alpha (TNFα) met the strong criteria for genome-wide significance in a recent meta-analysis of nearly 2,000 affected sibling pairs (21) . However, individual allelic associations with the different classes of HLA determinants are relatively weak. Genetic heterogeneity between different populations and the extensive linkage disequilibrium across this region (i.e., the coinheritance of germline variants due to the relative sparsity of recombination hotspots) have limited identification of the critical variants (22) . The HLA-DRB1 is the most extensively studied region in IBD with the strongest associations observed between HLA-DRB1 * 0103 and colonic CD and even more so with severe, extensive UC in whites (23) . Disappointingly, the low frequency of this allele hinders its use as a predictor of disease progression in clinical practice. In Japanese subjects, the allelic associations with HLA determinants are better defined, with a strong association with the HLADRB1 * 1502 allele evident (24) .
There is plausible evidence that more than one susceptibility locus within the larger HLA region is contributing to IBD. Genes such as TNFα are strong candidates, but to date, results of association studies (mainly focusing at the promoter region of TNFα because of its putative effect on gene expression) have been conflicting.
MDR1-Genetics of the Epithelial Barrier
The MDR1 gene (multidrug resistance 1/ATP binding cassette, subfamily B, member 1) is situated in an IBD susceptibility locus on chromosome 7q21 (21) . The MDR1 gene encodes P-glycoprotein 170, an efflux pump of amphipathic toxins, and is highly expressed at the apical surface of epithelia of the colon and distal small bowel (25) . MDR1 knockout mice are susceptible to developing a severe, spontaneous intestinal inflammation, which is preventable by and treatable with antibiotics (26). Onnie et al. performed a meta-analysis of 9 association studies of the C3435T variant and showed a significant association of the 3435T allele with UC, but not CD (27) . Using a gene-wide association strategy, Ho et al. recently demonstrated the association of germline variation of MDR1 with UC (28) . In this study, the strongest association was observed with extensive UC.
Current knowledge regarding the contribution of other candidate genes involved in maintenance of the epithelial barrier such as OCTNs, DLG5, and MyosinIXb is discussed in the "Candidates in Controversy" section below.
THE ERA OF GENOME-WIDE ASSOCIATION (GWA) STUDIES IN IBD: THE NEW KIDS ON THE BLOCK
The feasibility of genome-wide association studies promises to impact greatly on the field of IBD genetics and has already led to the discovery of several new putative susceptibility genes (Table 1) .
TNFSF15
A Japanese-British study reported the association between IBD and TNFSF15 (tumor necrosis factor superfamily, member 15 on 9q33.1, also called TNF superfamily ligand A, TL1A, or vascular endothelial cell growth inhibitor, VEGI) (29) . TNFSF15 is a novel TNF-like factor expressed primarily in endothelial cells with evidence for upregulation of mRNA 
Coding SNPs only; * G908R only, R702W failed genotyping and Leu1007finsC not part of the coding SNP panel.
† Only confidently identified in replication cohort, not in main genome-wide association study.
and protein levels in macrophages and CD4
+ /CD8 + lymphocytes of the intestinal lamina propria of IBD patients, especially CD (30) . The initial genome-wide study assessed 72,738 SNPs (single nucleotide polymorphisms) in 94 CD patients and 752 controls. In the second stage, 1,888 SNPs were identified (P < 0.01) for further genotyping in 484 CD patients. Of the 22 SNPs that were significant in this second stage (P < 1 × 10 −4 ), 7 were located within a region of ∼280 kb on chromosome 9q32 containing TNFSF15 and TNFSF8 loci. After detailed haplotype analysis of this region (involving a further 345 controls), the authors concluded TNFSF15 was the susceptibility gene on 9q32. In the same report, two independent white disease cohorts from the United Kingdom were analyzed. These cohorts were composed of a sample of 347 IBD trio families (161 CD, 175 UC, and 11 with indeterminate colitis) and 233 IBD multiplex families (containing 263 individuals affected with CD and 196 individuals affected with UC) and an independent sample of 363 CD patients and 372 healthy controls. Five polymorphic TNFSF15 markers were associated with the IBD phenotypes in the UK families and three also revealed suggestive evidence for CD association in the UK cases and controls. The same alleles showed greater risk of CD in the UK families and unrelated cases. Thus, high-and low-risk TNFSF15 haplotypes were identified in the Japanese and the UK cohort.
In an independent replication study, Kakuta et al. demonstrated a significant association of 6 SNPs across TNFSF15 in Japanese CD but not UC (31). Tremelling et al. showed association with CD of 2 out of 3 markers, defining the risk haplotype in TNFSF15 in 756 CD patients versus 636 controls from East Anglia (UK) (32).
IL23R
Recently, germline variation of IL23R (interleukin-23 receptor) has been implicated in conferring protection to ileal CD (33) . The North American consortium performed a genomewide association study testing 308,332 markers in 567 ileal CD patients and 571 controls of non-Jewish European ancestry. In the same report, Duerr et al. demonstrated replication of the protective effect of this rare IL23R allele (Arg381Gln, frequency 1.9% in non-Jewish ileal CD vs 7.0% in non-Jewish controls) in an independent case-control association study of Jewish ileal CD patients (N = 401 vs Jewish controls N = 433), as well as in a family-based association analysis (N = 833). The latter analysis also demonstrated association with non-Jewish UC.
IL-23 is a pivotal cytokine in the differentiation of T-helper cells, especially their differentiation into Th17 T cells (Fig. 3 ) (34) . In animal models, the Th17 T-cell subset has been shown to mediate chronic and autoimmune inflammatory conditions, with a central role for IL-23 in the development of intestinal disease (35) .
Tremelling and colleagues from the UK Wellcome Trust Case Control Consortium (WTCCC) replicated the protective effect of the rare IL23R allele in CD (N = 1,902) and UC (N = 975) versus healthy controls (N = 1,345) (36) . In addition, both this replication study and the index study described the association of other variants within the IL23R gene, independent of Arg381Gln. A family-based association study in pediatric IBD trios (151 CD/52 UC) showed a protective effect of Arg381Gln against IBD and CD, but not significantly against UC (37) . In our own cohort of childhood onset IBD, case-control analysis (IBD N = 358, controls N = 342) and family-based association analysis confirmed these findings (38) .
ATG16L1
German and British collaborators demonstrated association with a coding variant of ATG16L1 (autophagy-related 16-like 1) gene, on 2q37.1, thereby implicating the autophagy pathway of the innate immune system for the first time (39). Hampe et al. performed a genome-wide association study of 19,779 nonsynonymous SNPs in 735 CD patients and 368 controls, and 72 SNPs with P < 0.01 were subsequently analyzed in 380 CD trios, 498 CD patients, and 1,032 controls (39) . Association with one coding SNP (Ala197Thr, rs2241880) was replicated in these cohorts as well as in a replication cohort from the United Kingdom (CD N = 509 vs controls N = 656). Haplotype and regression analysis confirmed this variant carries virtually all the disease risk exerted by the ATG16L1 locus (39, 40) . In a second report from the North American ileal CD genome-wide association study, Rioux and colleagues replicated the association with ATG16L1 using case-control analysis in 988 CD patients versus 1,007 controls and family-based association analysis in 650 ileal CD trios (40) . The association of CD with ATG16L1 has also been replicated in a study from Oxford comparing 645 CD patients with 1,190 controls (41). The autophagy trafficking pathway was originally described as a cellular adaptation to starvation, whereby reprocessing of cell cytoplasmic ingredients is used to help sustain cellular anabolic needs. This mechanism is also critical in inhibiting Mycobacterium tuberculosis survival in infected macrophages (42) . ATG16L1 is expressed in the colon, small bowel, intestinal epithelial cells, leukocytes, and spleen, and multiple splice variants have been reported (39, 40) . No significant difference in expression of ATG16L1 was observed in CD versus control tissue and expression of ATG16L1 was independent of rs2241880 genotype (39) . Utilizing oligobased silencing RNA directed against ATG16L1 isoforms, autophagy induced by Salmonella Typhimurium was significantly different in ATG16L1 knockdown HEK293 cells when compared with control cells (40) .
Gene Deserts
A Belgian collaboration has identified a novel "gene desert" on chromosome 5p13.1 associated with CD, using a set of 317,497 markers in an initial analysis of 547 CD patients versus 928 controls. Replication studies and additional genotyping were performed in 1,266 CD patients versus 559 controls, and family-based association analysis involving 428 IBD trios, confirming the initial finding (43) .
Although no known genes or CpG islands are contained within this region, preliminary evidence suggests expression of at least one of the flanking genes, PTGER4 (prostaglandin receptor EP4), is regulated by CD-associated polymorphisms.
Additionally in this study, Libioulle and colleagues presented convincing replication data for both IL23R (CD and UC) and ATG16L1 (CD only).
The North American genome-wide association study has also implicated a genomic region that does not contain any known protein-coding genes (44). Rioux et al. hypothesized expression of one of the genes flanking this locus on chromosome 10q21.1, notably EGR2 (early growth response gene 2) could be regulated by this region.
The gene desert on chromosome 5p13 has been replicated by the WTCCC in the UK population (45) . This large study assessed 500,000 markers in 1,748 CD patients and 2,938 controls. Additionally, associations with gene deserts on chromosome 1q were replicated in 1,182 CD versus 5,746 nonautoimmune WTCCC cases and in the same 1,182 CD cases versus 2,024 independent population controls from the 1958 British Birth Cohort.
Novel associations with IRGM (an autophagy gene), NKX2-3 (NK2 transcription factor related, locus 3), and PTPN2 (protein tyrosine phosphatase, nonreceptor type 2) were also reported, and the established CD susceptibility genes NOD2/CARD15 and ATG16L1 showed strong evidence of association.
Access to sufficiently large cohorts for initial and replication analysis, stringent phenotype criteria, and interpretation of statistical thresholds have been key requirements for success in the studies discussed above. In spite of these successes, studies to date have also highlighted the potential limitations of genome-wide association strategies. In the Japanese study, only 94 patients (vs 752 controls) were genotyped for the 72,738 SNPs in the initial screen. This approach had a power to include true positive loci in the first screening at ∼50% probability if the relative risk (RR) associated with a SNP is >1.9 and the frequency of the risk-allele is 0.20 in case of the dominant-inheritance model (29) . As such, this study was underpowered to detect the association with IL23R (RR 1.72 in the study by Tremelling et al.) . Although the North American consortium, the Belgian collaboration, and Hampe et al. identified NOD2/CARD15, (two markers within the NOD2/CARD15 gene, one marker within NOD2/CARD15, and the G908R SNP of NOD2/CARD15 were identified, respectively), none identified Leu1007fsInsC (SNP13), and only the study by Hampe et al. and the WTCCC study were able to demonstrate association with the IBD5 locus. Rioux et al. argue the modest association with the IBD5 locus (P < 0.01) in the North American study is consistent with the modest risk conferred by this locus (see below for review of IBD5).
CANDIDATES IN CONTROVERSY
Complex polygenic disease genetics has been troubled with the "winner's curse" of index reports overestimating the effect size in discovery panels (36) . When replication studies are inconsistent, it has often been difficult to elicit with confidence whether true genetic heterogeneity exists (as has been demonstrated for NOD2/CARD15) or methodology shortcomings are to blame (e.g., study power, population stratification in control or patient group) (6). Below, we discuss a few IBD candidate genes, which have suffered from these problems. 
NOD1/CARD4
NOD1/CARD4, a structural homolog of NOD2/CARD15, is expressed more widely throughout the gastrointestinal tract (69) . Although, McGovern et al. initially reported an association between a complex intronic insertion/deletion polymorphism of NOD1/CARD4 and IBD, a number of wellpowered replication studies have not replicated this finding (70) (71) (72) . In order to provide a more robust assessment of the true contribution to disease susceptibility, we have performed a gene-wide association study using a set of markers "tagging" inherited variation of NOD1/CARD4. Using this strategy, we could not confirm a strong effect of germline variation of NOD1/CARD4 on IBD susceptibility (73) .
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Toll-Like Receptors
Toll-like receptors are another family of innate immunity PRRs, situated on the cell membrane and within endosomes. In recent years, a complicated network of regulatory pathways of TLR signaling has been described. The influence of NOD2/CARD15 signaling on TLR activation has received great research interest, but to date, no firm conclusions can be drawn from the available literature, as the precise mechanisms are likely to act in an organ-specific manner (2, 18) . Although a large number of studies have assessed the impact of TLR4 variants (especially the Asp299Gly polymorphism) on IBD susceptibility, results have been conflicting (2) . TLR9 (which binds unmethylated CpG dinucleotides) is recognized as an important player in intestinal homeostasis, with evidence for surface domain-specific (i.e., apical vs basolateral) signaling properties (74) . In a recent study, carriage of both the alleles TLR9 −1237C and CD14 −260T was increased in the chronic relapsing pouchitis group when compared with UC patients with infrequent pouchitis (75) .
DLG5
DLG5 (Drosophila discs large homolog 5) gene, a member of the MAGUK (membrane-associated guanylate kinase) family mapping to the pericentromeric IBD locus on chromosome 10, was first postulated as a CD suscepitiblity gene by Stoll et al. (76) . MAGUK proteins are known to form scaffolds for other proteins involved in intracellular signal transduction and could therefore interfere with the integrity of the epithelial barrier. Since the publication of the index paper, germline variation of DLG5 has been studied in a large number of populations but replication has only been demonstrated in a few (77) (Table 3 ) (51, 57, 60, 76, (79) (80) (81) (82) (83) (84) (85) (86) (87) (88) . Whether true genetic heterogeneity, phenotypic differences between patient populations, and/or stratification of control groups are responsible for these discrepancies remains a subject of intense debate, but a meta-analysis of most published studies suggests it does not have a major role to play in IBD susceptibility (78) .
MyosinIXb and ICAM-1
The IBD susceptibility locus on chromosome 19p (IBD6) has generated several IBD candidate genes, including ICAM-1 (intercellular adhesion molecule 1) and more recently the Myosin IX B (90, 91) . ICAM-1 is constitutively expressed in vivo on cells of the high endothelial venules and on germinal center cells in lymph nodes; in addition its expression is readily induced on leukocytes and different types of adherent cells. Myosin IX B is expressed in leukocytes and epithelial cells and thought to influence intestinal permeability. A detailed study looking at the contribution of 56 genes contained within the 19p locus, by Rioux's group was unable to replicate the association with ICAM-1 (92) . The association with Myosin IXb variant alleles has also come under scrutiny after publication of the first negative study by Amundsen et al.
.
WILL IBD GENETICS IMPACT ON CLINICAL PRACTICE?
To date, the use of a combination of environmental (e.g., smoking) and genetic markers to aid in the diagnosis of IBD has not been successful: increasing sensitivity has been troubled by decreasing specificity (94) . However, screening for NOD2/CARD15 variants in newly diagnosed CD patients has become available outside the research setting, and associations with a more complicated disease course (e.g., need for surgery) have been reported both in adults and children (95, 96) . Variability in drug response is greater across a population than in monozygotic twins or for a single patient, indicating a proportion of this response is genetically determined (97) . To date, the greatest impact the emerging field of pharmacogenetics has had on clinical practice has been the use of TPMT (thiopurine S-methyltranferase) genotyping to predict toxicity of azathioprine/6-mercaptopurine (recently reviewed by Pierik et al. (97) ).
Treatment response in IBD depends on a myriad of confounding factors including compliance with treatment, duration of disease, disease behavior/severity, function of drug metabolising enzymes, and underlying disease susceptibility/modifier genes. For example, high MDR1 expression has been found in IBD patients who fail medical therapy, and MDR1 polymorphisms have been associated with refractory IBD (98, 99) . However, the MDR1 3435 TT genotype (especially associated with extensive UC) leads to lower expression of MDR1 (97) .
Polymorphisms of DLG5 and the TNFα-promoter region have also been associated with steroid resistance (86, 100) .
In view of concerns regarding the safety profile of anti-TNFα therapy, especially the recent reports on hepatosplenic γ δ-T-cell lymphomata in pediatric IBD patients treated with azathioprine and infliximab, the need for prediction of response to these treatments has never been greater (101) . Several groups have studied single genetic markers to predict a patient's response to anti-TNFα therapy. NOD2/CARD15 variant carriage has unequivocally been shown not to be useful in this respect (102, 1030) . Polymorphisms of the TNFα promoter and its receptors have also failed to reliably predict response to infliximab (104) (105) (106) (107) . Variants of ADAM17 (a transmembrane metalloprotease involved in ectodomain shedding, the proteolytic release of extracellular portions of cell-surface molecules), FCGR3A (the gene encoding Fcγ RIIIa, a receptor for the Fc fragment of immunoglobulins on macrophages and natural killer cells), IBD5, caspase 9, and Fas ligand system (the latter two involved in apoptosis) may turn out to be better predictors, but further confirmation studies are required (108) (109) (110) (111) .
CONCLUSION
A decade of intensive research into genetic susceptibility has facilitated great advances in the understanding of the pathophysiology of IBD although the impact on diagnosis and treatment has been limited. Lately, the availability and Assessment of thiopurine S-methyltranferase (TPMT) genotype/activity to predict toxicity of azathioprine/6-mercaptopurine has clinical benefit and is cost-effective. NOD2/CARD15 genotype does not predict response to treatment. Other genetic determinants are currently being studied to aid in the selection of patients likely to respond to steroid therapy and anti-TNFα antibodies.
increasing number of consortia (at national and continental levels) are being formed to assess the genetic contribution to the increasing incidence of IBD worldwide, future successes will depend on setting research priorities based on stringent statistical criteria. Although NOD2/CARD15 variant carriage is associated with a more severe disease course in CD, notably need for surgery, NOD2/CARD15 genotype is not a good predictor of response to treatment. Other genetic determinants are being assessed to aid in the selection of patients for different treatment strategies, notably anti-TNFα treatment. Although, to date, none of these markers has made the transition from the research setting to clinical practice, the first real impact on patient's lives will likely be in tailoring of treatment strategies to the individual's carrier state of genetic risk factors. 
Summary
Glossary
Nonparametric linkage analysis
A statistical method that does not explicitly specify the mode of inheritance of a genetic marker used to detect linkage between genetic markers and a trait (1, 2) . Excess allele sharing in sought in affected relatives, which avoids the need to posit a disease model (3).
Candidate polymorphism study
A type of population association study focussing on a single nucleotide polymorphism (SNP) that is suspected of being implicated in disease causation or disease phenotype modification (3).
Candidate gene study
A type of population association study typically involving 5-50 SNPs within a gene (defined to include coding sequence, flanking regions, and splicing or regulatory sites). The gene can be either a positional candidate that results from a previous linkage study, or a functional candidate, based on knowledge about the pathophysiology of the disease under study (3) .
Fine mapping study
The kind of study conducted in a candidate region (e.g., identified through linkage analysis) to narrow the signal in a locus down to one gene from the 5-50 genes contained within a genomic locus. This type of study typically involves several hundred SNPs (3).
Genome-wide association studies
Advances in high-throughput chip-based genotyping technology have made it possible to study up to 1,000,000 wellchosen SNPs across the genome to identify common causal variants. Typically, a causal variant will not be typed in the study, possibly because it is not an SNP (it might be an inversion, insertion/deletion, or copy-number variation). These studies rely on the concept of linkage disequilibrium (where alleles occur together more often than can be accounted for by chance) between the chosen SNPs and the causal variants (3).
